Urology · Arlington, TX
NPI
1770579161
Since 2005
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
5005 S Cooper St Ste 250
Arlington, TX, 76017
Phone (866) 367-8768
Groups this clinician bills Medicare through
Medicare paid, 2024
$745K
11,016 services
Medicare patients, 2024
580
Average age 76
Drug cost, 2024
$9.6M
2,408 prescriptions
Company payments, 2025
$78K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James C Vestal was code J0897 (injection, denosumab, 1 mg), 2,460 times for 26 patients. In total James C Vestal billed 11,016 services in 113 codes, and Medicare paid $745K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-07-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 2,460 | 26 | $20.52 | $50K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 1,680 | 27 | $42.09 | $71K |
| 99214 Office E&M - Established | Office | 832 | 458 | $85.96 | $72K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 783 | 446 | $11.25 | $8,808 |
| 36415 Venipuncture Blood Collection | Office | 338 | 211 | $8.63 | $2,915 |
| 84153 Clinical Chemistry | Office | 257 | 149 | $17.87 | $4,593 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 251 | 53 | $44.60 | $11K |
| 81003 Clinical Chemistry | Office | 216 | 155 | $2.20 | $475 |
| 85027 Blood Count | Office | 193 | 118 | $6.25 | $1,206 |
| 84403 Clinical Chemistry | Office | 160 | 79 | $25.14 | $4,023 |
| 80053 Clinical Chemistry | Office | 146 | 77 | $10.24 | $1,495 |
| 51798 Ultrasound - Nonspecific | Office | 114 | 90 | $7.67 | $875 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 112 | 36 | $44.05 | $4,933 |
| 52000 Cystourethroscopy | Office | 92 | 64 | $171.53 | $16K |
| 51720 Chemotherapy Administration | Office | 58 | 12 | $63.16 | $3,663 |
By year: 2022 $387K for 9,848 services; 2023 $530K for 10,633 services; 2024 $745K for 11,016 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 338 | 211 | $8.63 | $2,915 |
| 84153 Clinical Chemistry | 257 | 149 | $17.87 | $4,593 |
| 81003 Clinical Chemistry | 216 | 155 | $2.20 | $475 |
| 85027 Blood Count | 193 | 118 | $6.25 | $1,206 |
| 84403 Clinical Chemistry | 160 | 79 | $25.14 | $4,023 |
| 80053 Clinical Chemistry | 146 | 77 | $10.24 | $1,495 |
| 80048 Clinical Chemistry | 56 | 50 | $8.29 | $464 |
| 81002 Clinical Chemistry | 44 | 15 | $3.41 | $150 |
Medicare prescription drug claims, 2024
In 2024, the drug James C Vestal prescribed most often to Medicare patients was Erleada (Apalutamide), with 470 prescriptions and refills. In total James C Vestal wrote 2,408 Medicare prescriptions that cost $9.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Erleada Apalutamide | 470 | 476 | 67 | $6.6M |
| Orgovyx Relugolix | 322 | 322 | 45 | $841K |
| Tamsulosin Hcl Generic | 303 | 847 | 102 | $4,021 |
| Finasteride Generic | 283 | 804 | 89 | $3,654 |
| Cephalexin Generic | 107 | 107 | 92 | $793 |
| Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen | 83 | 83 | 72 | $508 |
| Levofloxacin Generic | 82 | 82 | 68 | $343 |
| Xtandi Enzalutamide | 73 | 73 | Under 11 | $1.0M |
| Myrbetriq Mirabegron | 65 | 114 | 23 | $50K |
| Dutasteride Generic | 58 | 172 | 18 | $2,497 |
| Nubeqa Darolutamide | 52 | 52 | Under 11 | $701K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 46 | 54 | 39 | $499 |
| Gemtesa Vibegron | 38 | 58 | 12 | $29K |
| Abiraterone Acetate Generic | 36 | 36 | Under 11 | $149K |
| Ciprofloxacin Hcl Generic | 26 | 26 | 23 | $303 |
Brand drugs: 1,053 claims; generic drugs: 1,355 claims; opioid claims: 108.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James C Vestal $78K ($78K in general payments such as food, travel and fees) from 26 companies. The largest payer was Janssen Biotech, Inc. with $36K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 51 | $36K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 14 | $14K |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $8,448 |
| Dendreon Pharmaceuticals LLC | 15 | $5,948 |
| Ferring Pharmaceuticals Inc. | 4 | $4,060 |
| Avyxa Pharma, LLC | 6 | $3,626 |
| Astellas Pharma US Inc 4503.T | 5 | $3,067 |
| Immunitybio, Inc. IBRX | 8 | $408 |
| Urogen Pharma, Inc. URGN | 4 | $355 |
| Bioprotect Medical, Inc. | 5 | $296 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.